Posts

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN‑001 in Frontline Ovarian Cancer, Overcoming Historical IL‑12 Safety Barriers

on

Lilly’s Jaypirca scores another Phase III win in CLL, but use with Venclexta still evolving in practice

on

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

on

Allogene's Off-the-Shelf CAR-T Cema-Cel Shows Early Promise in Erasing Lingering Lymphoma Cells

on

FDA Issues Draft Guidance on MRD and CR Endpoints for Accelerated Multiple Myeloma Drug Approvals

on